Skip to main content Accessibility help
×
Home
  • Print publication year: 2007
  • Online publication date: March 2010

11 - Mantle cell lymphoma

from Part II - LYMPHOMA SUBTYPES

Summary

INTRODUCTION

Mantle cell lymphoma (MCL) is a unique subtype of non-Hodgkin's lymphoma (NHL) characterized in almost all cases by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression. Most patients present with advanced-stage disease, often with extranodal dissemination, and typically pursue an aggressive clinical course, with median survival historically averaging 3–4 years. No standard curative therapy exists, even with intensive induction regimens followed by autologous stem-cell transplantation. However, a number of recent insights into the molecular and cellular biology of the disease, as well as combined immunochemotherapy and novel therapeutic approaches, hold promise for improved outcomes. Importantly, MCL provides a paradigm for therapeutic targeting in neoplasms with dysregulated cell cycle and apoptotic pathways.

MCL comprises approximately 4–8% of all NHL, with a preponderance of older males relative to other lymphoma subtypes. The male-to-female ratio is 2–3 : 1 and median age at presentation is 60–65 years. No specific etiologic factors have been identified for this disease. An increased risk of lymphoid neoplasms has been reported in first-degree relatives of MCL patients, although MCL occurrence among multiple family members appears to be quite rare.

CLINICAL PRESENTATION

MCL typically presents in advanced stage; over 90% of patients are stage III–IV at diagnosis, frequently with B symptoms. Splenomegaly is seen in half or more of patients, often in association with a leukemic phase.

FURTHER READING
Dreyling, M., Lenz, G., Hoster, E.et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem-cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105 (2005), 2677–2684.
Fang, N. Y., Greiner, T. C., Weisenburger, D. D.et al. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc. Natl. Acad. Sci. USA 100 (2003), 5372–5377.
Fernandez, V., Hartmann, E., Ott, G., Campo, E. and Rosenwald, A.Pathogenesis of mantle cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J. Clin. Oncol. 23 (2005), 6364–6369.
Forstpointner, R., Dreyling, M., Repp, R.et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 104 (2004), 3064–3071.
Forstpointner, R., Unterhalt, M., Dreyling, M.et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108 (2006), 4003–4008.
Ghielmini, M., Schmitz Hsu, S. -F., Cogliatti, S.et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin. Oncol. 23 (2005), 705–711.
Gianni, A. M., Magni, M., Martelli, M.et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102 (2003), 749–755.
Gopal, A. K., Rajendran, J. G., Petersdorf, S. H.et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99 (2002), 3158–3162.
Hernandez, L., Bea, S., Pinyol, M.et al. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res. 65 (2005), 2199–2206.
Herold, M., Pasold, R., Srock, S.et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL). Blood 104 (2004), abstract 584.
Khouri, I. F., Lee, M. S., Saliba, R. M.et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J. Clin. Oncol. 21 (2003), 4407–4412.
Lefrere, F., Delmer, A., Levy, V. et al. Sequential chemotherapy regimens followed by high-dose therapy with stem-cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 89 (2004), 1275–1276.
Lenz, G., Dreyling, M., Hoster, E.et al. Immuno-chemotherapy with rituximab and CHOP significantly improves response and time to treatment failure but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 23 (2005), 1984–1992.
Maris, M. B., Sandmaier, B. M., Storer, B. E.et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 (2004), 3535–3542.
Quintanilla-Martinez, L., Davies-Hill, T., Fend, F.et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 101 (2003), 3181–3187.
Romaguera, J. E., Fayad, L., Rodriguez, M. A.et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus Hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J. Clin. Oncol. 23 (2005), 7013–7023.
Rosenberg, C. L., Wong, E., Petty, E. M.et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc. Natl. Acad. Sci. USA 88 (1991), 9638–9642.
Rosenwald, A., Wright, G., Wiestner, A.et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3 (2003), 185–197.
Swerdlow, S. H. and Williams, M. E.From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Human Pathol. 33 (2002), 7–20.
Tort, F., Hernandez, S., Bea, S.et al. Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 19 (2005), 112–117.
Zinzani, P. L., Magagnoli, M., Moretti, L.et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J. Clin. Oncol. 18 (2000), 773–779.